他汀与非他汀降LDL药物在二级预防中对心血管结局影响的随机试验荟萃分析
更强化治疗使主要血管事件相对风险降低19%(RR 0.81,95%CI 0.77-0.86),他汀与非他汀药物获益一致,LDL-C每降低1.0 mmol/L主要血管事件相对风险降低19%。
要点
- 更强化LDL-C降低使主要血管事件相对风险降低19%。
- 他汀强化与非他汀药物(PCSK9抑制剂、依折麦布)获益一致。
- LDL-C每降低1.0 mmol/L,主要血管事件相对风险降低19%。
核心结论
- 在二级预防中,主要血管事件的降低与LDL-C降低幅度成比例,涵盖广泛的治疗中LDL-C水平。
- 他汀强化以及联合PCSK9抑制剂或依折麦布治疗可显著降低这一极高危人群的心血管疾病风险。
研究设计与样本
- 检索Medline、EMBASE和Cochrane数据库,纳入他汀、依折麦布、PCSK9抑制剂或胆汁酸螯合剂的随机对照试验,要求患者数>500且随访≥1年。
- 采用随机效应模型,以风险比(RR)及95%置信区间(CI)比较结局。
主要发现
- 更强化治疗使主要血管事件(MVE)相对风险降低19%(RR 0.81,95%CI 0.77-0.86)。
- 基线LDL-C水平越高及LDL-C降低幅度越大,风险降低越显著。
- 他汀作为更强化干预的获益显著(RR 0.81,95%CI 0.76-0.86),非他汀药物(PCSK9抑制剂和依折麦布)亦显著(RR 0.85,95%CI 0.77-0.94),交互作用P=0.38。
- LDL-C每降低1.0 mmol/L,主要血管事件相对风险降低19%。
- 死亡、心血管死亡、心肌梗死、卒中和冠状动脉血运重建亦倾向于更强化治疗。
关键数值与推荐
- 更强化治疗使主要血管事件相对风险降低19%(RR 0.81,95%CI 0.77-0.86)。
- 他汀作为更强化干预的RR为0.81(95%CI 0.76-0.86),非他汀药物为RR 0.85(95%CI 0.77-0.94),交互作用P=0.38。
- LDL-C每降低1.0 mmol/L,主要血管事件相对风险降低19%。
临床怎么用
- 在二级预防极高危人群中,应强化他汀治疗以更大幅度降低LDL-C。
- 他汀基础上联合PCSK9抑制剂或依折麦布可进一步降低主要血管事件风险。
- LDL-C降低幅度是获益的关键,治疗中应追求更低的LDL-C水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Current evidence on dyslipidaemia management has expanded to novel treatments and very low achieved levels of low-density lipoprotein cholesterol (LDL-C). We sought to compare the clinical impact of more-intensive vs. less-intensive LDL-C lowering by means of statins and currently recommended non-statin medications in secondary prevention. METHODS AND RESULTS: We searched Medline, EMBASE, and Cochrane databases for randomized controlled trials of statins, ezetimibe, proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, or bile acid sequestrants with >500 patients followed for ≥1 year. We employed random-effects models using risk ratios (RRs) with 95% confidence intervals (CIs) to compare outcomes. We included 19 trials (15 of statins, 3 of PCSK9 inhibitors, and 1 of ezetimibe) with 152 507 patients randomly assigned to more-intensive (n = 76 678) or less-intensive treatment (n = 75 829). More-intensive treatment was associated with 19% relative risk reduction for the primary outcome, major vascular events (MVEs; RR 0.81, 95% CI 0.77-0.86). Risk reduction was greater across higher baseline levels and greater achieved reductions of LDL-C. The clinical benefit was significant across varying types of more-intensive treatment and was consistent for statins (RR 0.81, 95% CI 0.76-0.86) and non-statin agents (PCSK9 inhibitors and ezetimibe; RR 0.85, 95% CI 0.77-0.94) as active (more-intensive) intervention (P-interaction = 0.38). Each 1.0 mmol/L reduction in LDL-C was associated with 19% relative decrease in MVE. Death, cardiovascular death, myocardial infarction, stroke, and coronary revascularization also favoured more-intensive treatment. CONCLUSION: Reduction of MVE is proportional to the magnitude of LDL-C lowering across a broad spectrum of on-treatment levels in secondary prevention. Statin intensification and add-on treatment with PCSK9 inhibitors or ezetimibe are associated with significant reduction of cardiovascular morbidity in this very high-risk population.
引用
- Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018. PMID: 29069377. doi:10.1093/eurheartj/ehx566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。